TL;DR
This paper introduces a Bayesian methodology to identify novel cancer biomarkers associated with acquired resistance to lapatinib in breast cancer, focusing on signaling pathway disruptions and causal network modeling.
Contribution
It develops a Bayesian framework, PathTurbEr, for discovering driver biomarkers in signaling pathways using high-throughput gene expression data and causal Bayesian networks.
Findings
Identified 22 dysregulated signaling pathways in lapatinib resistance.
Developed a robust Bayesian network modeling approach for pathway analysis.
Revealed key pathways like PI3K-AKT and TGF-beta involved in resistance.
Abstract
Genes/Proteins do not work alone within our body, rather as a group they perform certain activities indicated as pathways. Signalling transduction pathways (STPs) are some of the important pathways that transmit biological signals from protein-to-protein controlling several cellular activities. However, many diseases such as cancer target some of these signalling pathways for their growth and malignance, but demystifying their underlying mechanisms are a very complicated tasks. In this study, we use a fully Bayesian approach to develop methodologies in discovering novel driver bio-markers in aberrant STPs given two-conditional high-throughput gene expression data. This project, namely PathTurbEr (Pathway Perturbation Driver), is applied on a global gene expression dataset derived from the lapatinib (an EGFR/HER dual inhibitor) sensitive and resistant samples from breast cancer cell…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
